Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akashi Therapeutics Inc.

www.akashitherapeutics.com

Latest From Akashi Therapeutics Inc.

Sarepta Snaps Up Gene Therapy Approaches to DMD

Sarepta may have launched its first therapy for Duchenne muscular dystrophy in the US, but it is facing potential competition from a plethora of late-stage DMD therapies; it is backing research that could lead to new gene therapies able to treat most affected patients, rather than a subgroup of individuals with a particular gene mutation.

Commercial Deals

DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?

Several companies have DMD drug candidates waiting in the wings to follow Sarepta’s Exondys 51 into the commercial market after FDA approval of the exon-skipping therapy, which could be the backbone for future combination treatment regimens.

Research and Development Strategies Neurology

Deals Shaping The Medical Industry, October 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced August-September 2014.

BioPharmaceutical Medical Device

Orphan Drug Economics: What’s The Right Price For Rare Disease Drugs?

The economics of orphan drugs have been pretty straightforward: Transformative treatments for rare diseases deserve premium prices. And so far, payors – at least the larger ones – haven’t really balked at those price tags. But stakeholders are starting to ask whether the orphan drug pricing benchmark set by Ceredase 20 years ago is right for all rare disease drugs. Industry needs to have good answers.

BioPharmaceutical North America
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Dart Therapeutics LLC
  • Dart Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Akashi Therapeutics Inc.
  • Senior Management
  • Marc B Blaustein, CEO
    Ernest D Bush, PhD, CSO
    Diana Escolar, MD, CMO
  • Contact Info
  • Akashi Therapeutics Inc.
    Phone: (617) 431-7250
    245 First St., 18th Fl.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register